Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation

Bo Cao1, Kebing Wang2, Jun-Ming Liao1

  • 1Department of Biochemistry and Molecular Biology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, United States.

Elife
|July 8, 2016
PubMed

Insights

The tumor suppressor p53 activates microRNA-139-5p (miR-139-5p) to inhibit phosphodiesterase 4D (PDE4D), a protein promoting cancer. This pathway halts tumor growth and is validated in colorectal cancer patients.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • MicroRNAs (miRNAs) are crucial in tumor suppression, often regulated by the p53 pathway.
  • Phosphodiesterase 4D (PDE4D) is an oncogenic protein implicated in various tumor-promoting processes.

Purpose of the Study:

  • To identify and characterize novel p53-regulated microRNAs involved in tumor suppression.
  • To investigate the role of miR-139-5p in the p53-mediated regulation of PDE4D and its impact on cancer cell growth.

Main Methods:

  • p53 and miR-139-5p expression analysis in cancer cell lines and human colorectal tumors.
  • Western blotting to assess protein levels of PDE4D and BIM.
  • Cellular cAMP level measurements.
  • Xenograft tumor growth assays in vivo.

Main Results:

  • p53 transcriptionally induces miR-139-5p, which targets and suppresses PDE4D protein levels.
  • Overexpression of miR-139-5p reduces PDE4D, increases cAMP, promotes BIM expression, and inhibits cell growth.
  • A significant inverse correlation between miR-139-5p and PDE4D expression was observed in colorectal tumors.
  • miR-139-5p overexpression suppressed xenograft tumor growth, decreasing PDE4D and increasing BIM.

Conclusions:

  • p53 inactivates the oncogenic PDE4D protein by inducing miR-139-5p expression.
  • The p53-miR-139-5p-PDE4D axis represents a novel tumor suppressive mechanism.
  • This pathway holds potential as a therapeutic target in cancers with altered p53 or PDE4D signaling.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K